Cipla Europe

• 

  Cipla Q2 Profit Falls As Europe, Emerging Markets Suffer

  Sales in India, Cipla's biggest market, rose 21 percent in the quarter, the company said in a statement.

• 

  Cipla Q4 Profit Lags On One-Off Charges In Europe, Emerging Markets

  Cipla Ltd, India's fifth largest drug maker by sales, reported a fall of 69 per cent in its quarterly earnings on Tuesday, far short of analysts' forecasts.

• 

  India Risks Missing Boat as Biosimilars Shake Up Drug Industry

  Chandru Chawla, head of Cipla Ltd's new ventures unit, said India's "fundamental disadvantage" over United States, Europe and South Korea was that biotechnology never evolved in India to the extent that chemistry did. "In terms of having the right knowledge ecosystem and the pools of talent, India is far behind," he said.

• 

  Cipla Surges 4.5%; Company to Sharpen Focus on Emerging Markets

  Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said.

• Cipla to Market Serum Institute's Paediatric Vaccines in Europe

  Cipla, which exports to over 170 countries, is working on expanding its presence in Europe, a region that contributed 5.7 per cent to the company's total revenue in the year to March 2013.

• Cipla in Commercial Tie-Up With UK's S&D Pharma

  Commenting on the announcement, Cipla, Europe Head, Frank Pieters said: "We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years."

• Cipla Launches Generic Respiratory Drug in Germany, Sweden

  Pharmaceutical major Cipla on Monday launched its generic drug used for treatment of asthma and chronic obstructive pulmonary disease in Germany and Sweden.

• Morgan Stanley downgrades Cipla, a day after Macquarie's upgrade

  The bank said the drugmaker's move to build a marketing and sales front-end operation in the United States and Europe will yield results only in the longer term.

• India Inc tops R&D investment growth global charts

  Indian companies have come on the top globally when it comes to growth in their research and development (R&D) investments, leaving their counterparts in the US and Europe far behind, a new study by the European Commission shows.

• India considers price controls for patented drugs

  India could rein in prices of patented drugs for its largely poor population but global drugmakers will likely oppose any such move.

• India considers price controls for patented drugs

  India is planning to rein in prices of expensive patented drugs to make medicines affordable.

• Top Cues: Asian shares fall to 3-month low on Europe turmoil

  Stock markets around the world see uncertainty ahead due to the situation in Europe.